Lars Olof Hedbys

Lars Olof Hedbys was the founder of Idogen AB, founded in 2008, and served as Chief Executive Officer in 2015.
Dr. Hedbys was also the founder of Iampatient AB..
Current positions included Chief Executive Officer & Director at Vagnlyftaren AB, Chairman at Strominnate Therapeutics AB, Deputy Director at CanImGuide Therapeutics AB, Independent Director at Xintela AB since 2021, Independent Non-Executive Director at Asgard Therapeutics AB since 2022, Director & Partner at Ventac Partners AB, Director at Cell Invent Sweden AB, Partner at Ventac Partners GmbH since 2013, and Partner at Ventac Partners A since 2006.
Former positions include Chief Executive Officer at Glycorex Transplantation AB, Mando AB, Pharmiva AB, and RhoVac AB (also Director), Chairman at Vetiqure AB, Lund Life Science Incubator, Scandinavian ChemoTech AB (2020–2023), and Smile Incubator AB (2011–2016), Director at Cartela AB, Regenesance BV, Hamlet BioPharma AB, and Chosa Oncology AB (2023–2024), Deputy Director at Immodulate Pharma AB, General Manager at Synarc A, Vice President at Astrazeneca Alpha BV in 2014, and Senior Advisor at Ventac Partners LLC.
Education includes graduate degree from Chalmers University of Technology and doctorate from Faculty of Engineering, Lund University.